Výsledky vyhledávání - "Kartik, Raghupathi"

Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma

Autor: Mark H. Moss, Njira L. Lugogo, Mario Castro, Nicola A. Hanania, Andrea Ludwig-Sengpiel, Dinesh Saralaya, Rafal Dobek, Iñigo Ojanguren, Ivan Vyshnyvetskyy, Jean-Marie Bruey, Robin Osterhout, Cindy-ann Tompkins, Karen Dittrich, Kartik Raghupathi, Hector Ortega

Publikováno v: Scientia

Asthma; Asthma worsening; Eosinophilic asthma Asma; Empitjorament de l'asma; Asma eosinofílica Asma; Empeoramiento del asma; Asma eosinofílica Background Prostaglandin D2 receptor 2 (DP2) antagonists inhibit prostaglandin D2-induced effects, includ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7cb6aa1f9e35d8b8f1d34f6669cbfc1
https://doi.org/10.1016/j.chest.2022.02.038

Zobrazit plný text záznamu

Results of a Phase 2b Trial With GB001, a Prostaglandin D

Autor: Mark H, Moss, Njira L, Lugogo, Mario, Castro, Nicola A, Hanania, Andrea, Ludwig-Sengpiel, Dinesh, Saralaya, Rafal, Dobek, Iñigo, Ojanguren, Ivan, Vyshnyvetskyy, Jean-Marie, Bruey, Robin, Osterhout, Cindy-Ann, Tompkins, Karen, Dittrich, Kartik, Raghupathi, Hector, Ortega

Publikováno v: Chest. 162(2)

Prostaglandin DWhat is the effect of the DPIn this phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, multicenter study, GB001 or placebo was added to standard-of-care treatment in patients with moderate to severe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::08a30a457306a46e34ea0b7ad0895bf2
https://pubmed.ncbi.nlm.nih.gov/35248549

Zobrazit plný text záznamu

Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis

Autor: Silvio Danese, Barrett G. Levesque, Brian G. Feagan, Alina Jucov, Bal Raj Bhandari, Rish K. Pai, Kristen Taylor Meadows, Brian J. Kirby, Jean‐Marie Bruey, Allan Olson, Robin Osterhout, Courtney Van Biene, Julia Ford, Richard Aranda, Kartik Raghupathi, William J. Sandborn

Publikováno v: Alimentary pharmacologytherapeutics. 55(4)

Epithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α, a transcription factor with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbeeeba47992d26a8f01ee2037f6d3a3
https://pubmed.ncbi.nlm.nih.gov/35245958

Zobrazit plný text záznamu

A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild‐to‐moderate asthma

Autor: Karen Dittrich, Dave Singh, Mary Fitzgerald, Caroline Pattwell, Hector Ortega, Jinshan Shen, Kartik Raghupathi, Cindy-ann Tompkins

Publikováno v: Clinical and Experimental Allergy

Background GB001 is an oral antagonist of the prostaglandin D2 receptor that may inhibit recruitment and activation of airway eosinophils, reducing airway inflammation. Objective To assess GB001 safety, efficacy and pharmacokinetics from a Phase 2 st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ae2b0aaf986d0bcbca874134eb577d3
https://doi.org/10.1111/cea.13524

Zobrazit plný text záznamu

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Autor: Kartik Raghupathi, Jeffrey A. Cohen, Neil Minton, Xavier Montalban, Ludwig Kappos, Krzysztof Selmaj, Eva Havrdova, James K Sheffield, Lawrence Steinman, Douglas L. Arnold, Radiance Trial Investigators, Vivian Huang, Bruce A.C. Cree, Amit Bar-Or, Hans-Peter Hartung, Giancarlo Comi

Publikováno v: The Lancet Neurology. 18:1021-1033

Summary Background Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclero

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e346bfdf1d04f995be7cc355022e9646
https://doi.org/10.1016/s1474-4422(19)30238-8

Zobrazit plný text záznamu

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Autor: Giancarlo Comi, Neil Minton, Ning Ding, Amit Bar-Or, Ludwig Kappos, Lawrence Steinman, Eva Havrdova, Sunbeam Study Investigators, Bruce A.C. Cree, Krzysztof Selmaj, Xavier Montalban, Kartik Raghupathi, Hans-Peter Hartung, Jeffrey A. Cohen, James K Sheffield, Douglas L. Arnold

Publikováno v: The Lancet Neurology. 18:1009-1020

Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable safety prof

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13821c045195837b6bb9e0d1f95dfa67
https://doi.org/10.1016/s1474-4422(19)30239-x

Zobrazit plný text záznamu

Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36)

Autor: Johanna C. Bendell, Jack Shiansong Li, Wungki Park, John H. Strickler, Haeseong Park, Kartik Raghupathi, Wells A. Messersmith, Laura L. Carter, Jean-Marie Bruey, Drew W. Rasco, Jakob Dupont, Marya F. Chaney, Johann S. de Bono, Lei Zhou

Publikováno v: Journal of Clinical Oncology. 39:2505-2505

2505 Background: GB1275 is a first-in-class, oral CD11b modulator that reduced myeloid-derived suppressor cells (MDSCs) and tumor associated macrophages (TAMs), repolarized M2 immunosuppressive TAMs to an M1 phenotype, resulting in increased tumor in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a91bdba1ba15444442855772db65feb4
https://doi.org/10.1200/jco.2021.39.15_suppl.2505

Zobrazit plný text záznamu

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

Autor: Eva Havrdova, Michael Hutchinson, Ralf Gold, Marianne T. Sweetser, Katherine Dawson, Nuwan Kurukulasuriya, Kartik Raghupathi

Publikováno v: Expert Opinion on Pharmacotherapy. 14:2145-2156

Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system involving inflammation, chronic demyelination and axonal loss. MS affects more than 2 million people worldwide.This article aims to summarize the finding

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feaa7f03888a2d998ac81c6f8b666c5d
https://doi.org/10.1517/14656566.2013.826190

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání